Pregabalin Capsule
Product Images NDC 58118-0761

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 58118-0761). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Equation (Pregabalin Equ)

The image displays a pharmacokinetic calculation formula for creatinine clearance (CLCr). The formula includes variables for age (years), weight (kg), serum creatinine (mg/dL), and a multiplier of 0.85 for female patients. This text panel provides a mathematical method relevant to drug dosing considerations.*

FDA Label Image

Figure 1: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Dpn 1 (Pregabalin Fig1)

A line chart illustrating the percent of patients achieving various levels of improvement in pain intensity in Study DPN 1 for Pregabalin capsules taken orally at doses of 25 mg, 100 mg, and 200 mg three times a day, compared to placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percent of patients improved. The chart shows higher doses of Pregabalin correspond to greater percentages of patient improvement across the pain improvement spectrum.*

FDA Label Image

Figure 10 (Pregabalin Fig10)

A Kaplan-Meier analysis graph titled 'Time to Loss of Therapeutic Response, Fibromyalgia Study F2' comparing Pregabalin and placebo over 180 days. The y-axis shows the estimated percentage of subjects without loss of therapeutic response (LTR) from 0% to 100%, and the x-axis shows time in days. Two curves represent the subjects on Pregabalin and placebo, illustrating differences in response loss over time.*

FDA Label Image

Figure 11 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved from baseline to week 12 using the Brief Overall Change Form (BOCF). The x-axis represents percent improvement ranging from 0 to 100, while the y-axis indicates the percent of subjects improved, also from 0 to 100. Two lines display data for Pregabalin and Placebo groups, showing a higher proportion of subjects improved with Pregabalin over the placebo.*

FDA Label Image

Figure 12 (Pregabalin Fig12)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to week 16 using the BOCF method. The graph shows two lines representing Pregabalin and placebo. The x-axis represents percent improvement from 0 to 100, and the y-axis represents the percent of subjects improved from 0% to 100%. The Pregabalin line consistently shows higher improvement rates compared to placebo across the range. Vertical lines mark specific percentage points at 10, 30, 50, and 80 percent improvement.*

FDA Label Image

Pregabalin 25mg Capsule 30ct Blister Card (Pregabalin Fig13)

Label for Pregabalin 25 mg oral capsules by Clinical Solutions Wholesale, LLC. The package contains 30 capsules. The label includes National Drug Code (NDC) 58118-0758-8 and manufacturer information for Aurobindo Pharma Limited, East Windsor, NJ, USA. It also displays a batch number, expiration date of September 2027, and a QR code.*

FDA Label Image

Pregabalin 50mg Capsule 30ct Blister Card (Pregabalin Fig14)

Packaging label for Pregabalin 50 mg capsules by Clinical Solutions Wholesale, LLC. The label includes the National Drug Code (NDC) 58118-0759-8, quantity of 30 capsules, and manufacturing details from Aurobindo Pharma Limited. Additional information includes batch and serial numbers, expiration date of September 2027, and distributor address in Franklin, Tennessee.*

FDA Label Image

Pregabalin 75mg Capsule 30ct Blister Card (Pregabalin Fig15)

Label for Pregabalin 75 mg capsule by Clinical Solutions Wholesale, LLC. The label includes the NDC 58118-0760-8, quantity 30 capsules, and manufacturer information indicating the drug is manufactured by Aurobindo Pharma Limited in East Windsor, NJ. It also shows batch number SAMPLE456 and expiration date September 2027.*

FDA Label Image

Pregabalin 100mg Capsule 30ct Blister Card (Pregabalin Fig16)

Packaging label for Pregabalin 100 mg capsules by Clinical Solutions Wholesale, LLC. The label indicates a quantity of 30 capsules per package, with NDC 58118-0761-8. Manufactured by Aurobindo Pharma Limited in East Windsor, NJ, USA, the label includes GTIN and batch numbers, along with an expiration date of September 2027.*

FDA Label Image

Pregabalin 150mg Capsule 30ct Blister Card (Pregabalin Fig17)

Pregabalin 150 mg capsule packaging label from Clinical Solutions Wholesale, LLC. The label shows the NDC number 58118-0762-8 and indicates a quantity of 30 capsules. It lists the manufacturer as Aurobindo Pharma Limited, East Windsor, NJ, USA, with batch and serial numbers, and expiration date 2027 Sep. The label includes a barcode and a QR code.*

FDA Label Image

Pregabalin 200mg Capsule 30ct Blister Card (Pregabalin Fig18)

Pregabalin 200 mg capsule packaging label showing the product name, strength, dosage form, and quantity of 30 capsules. It includes the NDC number 58118-0763-8, manufacturer information for Avrobindo Pharma Limited located in East Windsor, NJ, USA, and repackaging details by Clinical Solutions Wholesale, LLC in Franklin, TN. The label also displays batch number SAMPLE456 and an expiration date of 2027, with a QR code and barcode present.*

FDA Label Image

Pregabalin 225mg Capsule 30ct Blister Card (Pregabalin Fig19)

Label for Pregabalin 225 mg oral capsules by Clinical Solutions Wholesale, LLC. The label shows the National Drug Code (NDC) 58118-0764-8 and a quantity of 30 capsules. Manufacturer information lists Aurobindo Pharma Limited, East Windsor, NJ, USA, with batch and expiration details. The label includes barcodes and distribution address in Franklin, TN.*

FDA Label Image

Figure 2: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study (Pregabalin Fig2)

A line chart titled 'Patients Achieving Various Levels of Improvement in Pain Intensity – Study DPN 2' comparing Pregabalin 100 mg three times a day versus placebo. The x-axis shows percent improvement in pain from baseline (0 to 100%), and the y-axis indicates percent of patients improved (0 to 100%). Two lines represent the proportion of patients achieving different levels of pain improvement over the study period.*

FDA Label Image

Pregabalin 300mg Capsule 30ct Blister Card (Pregabalin Fig20)

Pregabalin 300 mg capsule label from Clinical Solutions Wholesale, LLC. The label includes the NDC number 58118-0765-8, a quantity of 30 capsules, manufacturer Aurobindo Pharma Limited in East Windsor, NJ, and repackager address in Franklin, TN. The label also shows GTIN, batch number, and a QR code for scanning.*

FDA Label Image

Figure 3: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 1 (Pregabalin Fig3)

A line graph titled 'Patients Achieving Various Levels of Improvement in Pain Intensity - Study PHN 1'. The x-axis shows percent improvement in pain from baseline (0 to 100%), and the y-axis shows percent of patients improved (0 to 100%). Four lines represent Pregabalin doses 300 mg, 150 mg, 75 mg two times a day, and placebo, illustrating the percentage of patients achieving different levels of pain improvement.*

FDA Label Image

Figure 4: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 2 (Pregabalin Fig4)

A line graph titled 'Patients Achieving Various Levels of Improvement in Pain Intensity – Study PHN 2' showing percent of patients improved on the y-axis and percent improvement in pain from baseline on the x-axis. It compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating their respective efficacy levels in pain improvement over a range from 0 to 100 percent.*

FDA Label Image

Figure 5: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 3 (Pregabalin Fig5)

A line graph titled 'Patients Achieving Various Levels of Improvement in Pain Intensity – Study PHN 3' comparing percentage of patients improved versus percent improvement in pain from baseline. It shows three lines representing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph highlights higher patient improvement percentages for Pregabalin doses compared to placebo across varying levels of pain improvement.*

FDA Label Image

Figure6 (Pregabalin Fig6)

A bar graph comparing responder rates (%) in two studies labeled Study E1 and Study E3 for Pregabalin oral capsules at various dosages, including placebo controls. The x-axis shows dose groups and the y-axis shows responder rates from 0% to 60%. Study E1 includes placebo and 50, 150, 300, 600 mg/day doses given BID. Study E3 includes placebo and 600 mg/day doses given BID and TID. Bars indicate increasing responder rates with higher doses and frequency compared to placebo.*

FDA Label Image

Figure7 (Pregabalin Fig7)

A line graph comparing median percent seizure reduction from baseline against dose in mg/day for Pregabalin across four studies (E1 BID, E2 TID, E3 BID, and E3 TID). The graph shows increasing seizure reduction with higher doses, with statistical significance indicated by p-values, all less than or equal to 0.0001 or 0.0007 for some points, and placebo referenced at zero dose.*

FDA Label Image

Figure 8 (Pregabalin Fig8)

A bar chart showing responder rates (%) for placebo and two doses of Pregabalin (2.5 mg/kg/day and 10 mg/kg/day). Responder rates increase from 22.6% for placebo to 29.1% for the lower dose and 40.6% for the higher dose. Sample sizes are shown below each group.*

FDA Label Image

Figure 9 (Pregabalin Fig9)

A line graph titled 'Patients Achieving Various Levels of Improvement in Pain Intensity – Fibromyalgia Study F1' showing the percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. It compares outcomes for Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg, against a placebo. The graph displays decreasing percentages of patients achieving higher levels of pain improvement across all treatments.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, showing its molecular arrangement with labeled functional groups including a carboxylic acid moiety and an amino group attached to the carbon backbone.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.